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MYELOABLATIVE CONDITIONING WITH TBI/VP-16 WITH ALLOGENE- 
IC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: HIGH 
RESPONSE RATE AND PROLONGED PROGRESSION FREE SURVIVAL 
GoldsteiJl, S.C.; PerkiJ~s, J.; Field, 72; .Tam'sell, ~V.; Als'i~a, I.; &dli- 
va,*, D.; Fields', K.; Smith, C. H. Lee Moffitt Ca~ce'l" Ce~te'l" aJzd 
Researeh IHstimte at the UMversity of SoHth Florida, Tampa, FL. 
Although High Dose Therapy with autologous peripheral blood 
stem cell transplantation has improved the complete response rates 
and overall survival for patients with Multiple Myelolna (MM), mak- 
ing it the standard of care for many patients (pts) with chemosensitive 
disease; autotransplantation has not demonstrated curative potential 
despite xtensive valuation with long-term follow-up. Despite the 
demonstration f an immunologic graft vs myeloma effect, the overall 
success of myeloablative conditioning with allogeneic transplantation 
for patients with MM has been limited hy treatment related mortality 
(TRM) as well as relapse. Whereas novel strategies such as non-mye- 
loablative conditioning may lower the early TP~M, they have thus far 
have had only marginal success in long term disease control. Novel 
myeloablative conditioning regimens with acceptable to ,  city car W 
the potential advantage of tumor cytoreduction a d establishment of 
donor chimerism to improve long term disease control. We report 
the long term follow-up of 14 consecutive patients with MaVI who 
have undergone myeloablative conditioning witln either BuCy2 (n=7) 
or TBI/VP-16 (n=7) followed by allogeneic bone nmrrow stem cell 
transplantation fi'om HLA-identical sibling donors. Median age for 
all patients i 46 years. The probability of Overall Survival (OS) at 2.5 
years for all patients, BuCy2 pts, and TBI/VP-I6 pts is 36% (SE 
13%), 14% (SE 13%), and 57% (SE I9%), respectively. The proba- 
bility of Event Free Survival (EFS) at 2.5 yrs is identical to the OS. 
Of note, the probability of Progression-Free Survival (PFS) at 2.5 
years, in which treatment related deaths are censored, is 78% (SE 
14%) for all pts, 50% (SE 25%) for BuCy2 pts, and 100% for 
TBI/VP-16 pts. Surviving patients after myeloablative conditioning 
have been followed without relapse for a minimum of 4 years. 100 day 
TPdVI for all pts was 28%. Although this analysis is limited by sample 
size, these results demonstrate prolonged disease free survival for pts 
with MM after myeloablative conditioning with hig'h dose TBI/VP- 
16 followed by allogeneic stem cell transplantation. This regimen is 
well tolerated and warrants further investigation as a potentially cura- 
tive strategy in young MM patients with HLA-identical donors. 
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NON-MYELOABLATIVE STEM CELL TRANSPLANTATION (SCT) IS SAFE 
AND EFFECTIVE FOR PATIENTS WITH MULTIPLE MYELOMA 
Mm'eb, J.s.l; Cogle, C.RJ; Leather, H.L.e; Wiggins, L.~-; Fi1~iewiez, 
K.J.~; Kha*z, S.A.~; Reddy, ~':S.e; ~'t')'J~gard, ff.R. ~ 1. ~J)#vevsitj of 
FloT"ida College of Medici1~e, GaiT~esville, FL; 2. Shallcls Hospital Braze 
3la'lvvoa, TvaJzsplaT~a Program, Gai,~esville, FL. 
Allogeneic SCT can be curative in multiple myeloma (NLM), 
however the high transplant related morbidity and mortality 
(TRM) limit this therapy to young, low-risk patients. Purpose: 
The purpose of this study was to determine safety and efficacy of 
non-myeloablative stem cell transplant (NST) for high-risk 
patients with MM. Patients and Methods: From September 1999 
to June 2001, eight MM patients with a median age of 49 years 
(range, 44 to 62), received allografts from HLA-matched siblings 
(n=6) or unrelated onors (n=2). Prior to NST none were in com- 
plete remission (CR) and 4 had progressive disease (PD). Six 
patients had a prior autologous transpFant. Median time from 
diagnosis to NST was 33 months (range , 5 to 64). The condition- 
ing regimen included flndarabine, finti-thymocyte globulin and 
busulfan. Peripheral blood stem cell grafts were administered to
all patients. Results: All patients had prompt myeloid and platelet 
engraftment. Acute graft versus host disease (GVHD) (three grade 
I, two grade IIi) occurred in 5 of 8 patients (62%), at a median 
time of 26 days (range, 11 to 106 days). Four patients (50%) 
developed chronic GVHD (2 limited, 2 extensive). Two patients 
with no GVHD and PD received onor leukocyte infusion (DLI) 
(lxl0 s CD3/kg). One patient receiving DLI subsequently devel- 
oped grade I acute GVHD. The conditioning regimen was well 
tolerated with no patients developing VOD or severe mucositis. 
During neutropenia, only one patient developed a line-associated 
gram positive bacteremia. While on immunosuppressants, seven 
patients developed opportunistic nfections, including CMV and 
HSV colitis, cutaneous zoster, polyoma BK cystitis, mucocuta- 
neous candidiasis, puhnonary aspergillosis and Strongyloides 
infection. Only one patient died of opportunistic infection. With a 
median follow-up of 13 months, three (38%) achieved CR, two 
(25%) PR, one MR, one SD, and one PD. M1 disease responses 
were observed after development of GVHI). Two patients (25%) 
died before 100 days: one of CNS failure secondary to possible 
FK506 toxicity and another due to opportunistic lung infection. 
One year EFS and OS are 50% and 75%, respectively. Conclu- 
sions: NST with fludarabine, anti-thymocyte globulin and busul- 
fan conditioning is well tolerated in high>risk patients with MM. 
In addition, agraft versus lnyeloma effect is obsmwed. 
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL 
TRANSPLANTATION (AUTO SCT) FOLLOWED BY REDUCED INTENSI- 
TY (RI) ALLOGENEIC TRANSPLANTATION (ALLO SCT) IN CHILDREN 
AND YOUNG ADULTS WITH RELAPSED LYMPHOMA 
Bradley, 31.; Hal"l"isoT1, L.; George, D.; Ga'l'viJz, ft.; Del Tovo, G.; 
Wolozwdk, K.; CTJe~mg, }:; WeiTler, 3'1.; Kelly, 1,2; Sleervitt, D.; G#~'o, 
M.S. Cbildre~'s Hos'pital of Nezv Yo*'/e PJ'e,rl{yteJ'#m, New Y0r'k, NI~ 
Patients with relapsed I tD and NHL treated with MA 
AutoSCT have a high risk of relapse (40-60%) and secondary 
MDS/AML (5-20%). MA AlloSCT may confer a graft versus lym- 
photos effect but with considerable regimen-related mortality 
(Jones et al, Blood 77:649, 1991). Recently, Carella et al (JCO 
18:3918, 2000) demonstrated the feasibility of MA AutoSCT fol- 
lowed by RI AlloSCT in adults with refractory HD. X/Ve investi- 
gated MA AutoSCT followed by RI AlloSCT in relapsed pediatric 
HD/NHL. MA: Cyclo 1500 mg/m 2 x 4d, BCNU 100 nlg/ln 2 x 3d, 
VP-16 800 mg/m 2 x 3d, and AntoSCT. After recovery, patients 
with CD20 + lymphoma (3/4) received Rituximab (375 
mg/me/wk/x 4), and all patients received IFRT (2-3 Gy). RI: Flu 
30 mg/m 2 x 5d, Bn 3.2 mg/kg x 2d, and Thymoglobulin® 2.0 
mg/kg x 4d (UCB recipients only) and MloSCT (1 related 6/6 
PBSC, 3 4/6 UCB). GVHD prophylaxis: FK506 (0.03 mg/kg 
CM)  on day-1 - +60 (wean started) and MMF (15 lng/kg) day +1 
- +28. There were 3 t tD (2 CR + 1 PR after Ifos/Carbo/Etop 
reinduction), age 17, 18, and 22 years, 1 stage IIA, 1 stage IIIB, 1 
stage IVA, and I anaplastic large cell ymphoma (ALCL) (PR after 
Topo/Ifos/Carbo reinduction) age 11. Tandem MA AutoSCT + 
RI MloSCT was well tolerated. Median time to RI MloSCT after 
MA AutoSCT was 124 d. Median F/U is 380 d. One pt has grade 
3 hematuria nd grade 2 pulmonary toxicity. Following RI 
MloSCT, myeloid recovery occurred on day +15 (MRD) day +15, 
+18, +23 (UCBT), platelet recovery on day +11 (MRD), day +25, 
+31, +170 (UCBT). The 3 HD patients have 100% donor 
chimerism and are NED at day +474, +286 and +473, respectively, 
and the pt with NHL is 95% donor and NED at day +140. No 
patient developed AGVHD. One patient developed limited 
chronic liver GVHD responding to alternating CSA + Pred. Esti- 
mated OS at 1 year is 100%. In conclusion, MA AutoSCT fol- 
lowed by IFRT, targeted monoclonal antibody therapy, and RI 
Mlo SCT is feasible and well tolerated in pediatric patients with 
relapsed HD/NHL.  A larger study with longer follow up is 
required to determine if this approach will reduce relapse and/or 
MDS and improve EFS. 
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THE CHOICE OF CONDITIONING REGIMEN REGARDING THE HOST T- 
CELL LEVELS SEEMS TO BE AN EFFECTIVE WAY HOW TO ACHIEVE 
THE DONOR CELLS ENGRAFTMENT INCLUDING EFFECTIVE TUMOUR 
C*ONTROL AND REDUCE THE TOXICITY OF SOME NON-MYELOABLA- 
TIVE ALLOGENEIC STEM CELL TRANSPLANTATIONS IN LYMPHOMAS 
Raids, L.; Faber, E.; Papajfk, 72; Heczko, M.; Skolmlalovd, I.; Pikalovd, 
Z.; Jaroovd, 3/I.; Koztpilovd, 3 i.; ~'7achovd, .; Kltbahikovd, R.; Di'coted, ~I., 
h~d~vik, I(; Htcbd?ek, ,7. mdversi O, Hospital, Olo~.oztc, Czech RepTzblic. 
"Graft versus iymphoma" (GvL) reaction plays the key role in 
the tmnonr control of patients undergoing allogeneic stem cell 
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